NASDAQ:CRVS - Corvus Pharmaceuticals, Inc.
$4.15
 $0.06
+1.47%
1:35PM EDT
2019-02-15
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CRVS     avg for
industry  
  avg for
sector  
42 stocks weight:  53. 50   0. 00   0. 00  
42 stocks rank:  2. 64 K 1. 86 K 1. 09 K
# analyst opinions:  3. 00   14. 92   14. 43  
mean recommendation:  1. 30   1. 91   1. 93  

quick ratio:  15. 87   5. 37   1. 81  
current ratio:  16. 07   5. 69   2. 19  

target price low:  4. 77   88. 97   117. 82  
target price avg:  5. 41   115. 19   141. 96  
target price high:  6. 05   143. 40   163. 16  
1-yr high:  13. 73   124. 30   142. 77  
last close:  4. 09   101. 85   127. 84  
50-day avg:  4. 43   98. 27   122. 46  
200-day avg:  8. 40   99. 72   122. 70  
1-yr low:  3. 29   78. 19   100. 16  
volume:  33. 80 K 2. 38 M 4. 64 M
50-day avg volume:  111. 80 K 3. 31 M 4. 94 M
200-day avg volume:  90. 93 K 3. 23 M 4. 28 M

1-day return:  -4. 22 % 0. 22 % 0. 48 %
this week return:  -3. 08 % 1. 77 % 2. 01 %
12-wk return:  -38. 03 % 6. 56 % 3. 33 %
52-wk return:  -49. 33 % -2. 23 % 14. 35 %

enterprise value (EV):  -1. 70 M 55. 17 B 104. 51 B
market cap:  119. 76 M 49. 01 B 96. 46 B
EBITDA:  -49. 35 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 04   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -48. 36 M 2. 37 B 3. 58 B

shares outstanding:  29. 28 M 607. 99 M 1. 22 B
shares:  11. 90 M 605. 53 M 1. 15 B
shares short:  1. 08 M 11. 62 M 12. 55 M
shares short prior month:  1. 04 M 11. 95 M 13. 44 M
short ratio:  9. 92   4. 82   3. 10  
short % of float:  7. 85 % 6. 19 % 2. 82 %
total cash/share:  4. 19   12. 02   11. 46  
total cash:  122. 64 M 7. 41 B 7. 37 B
free cash flow:  -26. 61 M 95. 99 M 2. 04 B
operating cash flow:  -43. 71 M 164. 74 M 3. 04 B

book value:  4. 06   14. 43   28. 26  
price/book:  1. 01   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  16. 35 % --- ---
1-yr mean volatility:  -0. 19 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 91   3. 03   4. 09  
forward EPS:  -1. 81   4. 33   6. 99  
P/E:  -2. 14   6. 11   26. 91  
forward P/E:  -2. 36   8. 38   10. 48  
PE/G:  0. 13   0. 37   5. 61  
growth:  -15. 93 % 683. 72 % 104. 79 %
earnings high:  -0. 39   1. 27   1. 66  
earnings avg:  -0. 43   1. 01   1. 53  
earnings low:  -0. 50   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -27. 07 % -3. 27 % 3. 81 %
return on equity:  -45. 50 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  1. 13   1. 21   0. 93  
sharpe (1yr):  -0. 72   0. 06   0. 98  

held % insiders:  5. 41 % 6. 46 % 3. 21 %
held % institutions:  87. 99 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : CRVS
.    + 0.114 =         0.114 :: INITIAL WEIGHT
.  + 592.579 =       592.693 :: inverse volume-to-price addition
.  + 212.214 =       804.907 :: spline projection addition
.  - 170.006 =         634.9 :: poor performance penalty
.    x 0.692 =       439.186 :: one-year gains+dividend factor
.    x 4.813 =      2113.774 :: 13 weeks' performance factor
.    x 1.492 =      3154.784 :: industry recommendation factor
.    x 2.697 =      8508.237 :: symbol recommendation factor
.    x 0.997 =      8485.207 :: return on assets factor
.    x 0.995 =      8446.603 :: return on equity factor
.    x 2.823 =     23844.856 :: current ratio factor
.    x 1.033 =     24633.432 :: quick ratio factor
.    x 1.049 =     25845.231 :: short ratio factor
.     x 2.01 =     51950.888 :: price-to-book factor
.    x 5.697 =    295941.292 :: EBITDA multiple factor
.    x 2.164 =    640284.388 :: P/E weight
.    x 1.651 =   1057218.834 :: PE/G factor
.    x 1.765 =   1865984.559 :: beta factor
.    x 0.724 =   1351775.975 :: sharpe factor
.     x 1.42 =   1918856.012 :: target low factor
.    x 1.189 =    2282398.31 :: target mean factor
.    x 1.069 =    2440313.42 :: target high factor
.    x 1.066 =   2600429.233 :: industry 12-weeks return
.    x 0.995 =   2588154.726 :: "drift" penalty 4 days ago
.    x 0.926 =    2397039.82 :: "drift" penalty 5 days ago
.      x 1.0 =   2396721.654 :: overall "drift" factor
.    x 0.837 =   2004887.121 :: largest single-day jump factor
.    x 0.076 =    153161.736 :: low price factor
.      x 1.0 =    153172.016 :: factor hist industry gain for week 06
.   cubeRoot =        53.505 :: reduced for readability
.                     53.505 :: FINAL WEIGHT for NASDAQ:CRVS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org